Pennsylvania’s First Xarelto Lawsuit Trial Concludes With $28 Million Verdict for Plaintiff, Bernstein Liebhard LLP Reports


NEW YORK, Dec. 8, 2017 — A Pennsylvania jury hearing evidence in the state's first trial of a Xarelto lawsuit has awarded $28 million to an Indiana woman who suffered a gastrointestinal bleeding a little over a year after she was prescribed the new-generation blood thinner.

Monday's verdict followed nearly a month of testimony in the Philadelphia Court of Common Pleas, where the Plaintiff's attorneys accused Bayer and Johnson & Johnson of downplaying the true potential for Xarelto to cause life-threatening episodes of internal bleeding. The jury deliberated for fewer than two days before awarding the Plaintiff and her husband $1.8 million in actual damages and $26 million in punitive damages. (Case No. 160503416)

“Our Firm is representing a number of Xarelto lawsuit plaintiffs who allegedly suffered gastrointestinal bleeds, cerebral hemorrhage and other serious episodes of internal bleeding due to this medication. We are extremely pleased that this jury returned a verdict for the plaintiff, as this case was a bellwether trial and was intended to provide insight into how other juries in the Pennsylvania mass tort program might rule in similar Xarelto bleeding claims,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.

Xarelto Bleeding Lawsuits

Bayer and Johnson & Johnson have been named defendants in more than 20,000 Xarelto lawsuits, including around 2,000 that are part of the mass tort program underway in Philadelphia.

Plaintiffs pursuing these claims allege that Johnson & Johnson and Bayer failed to provide doctors and patients with adequate warnings regarding the potential for Xarelto to cause serious internal bleeding. The companies have also been accused of misleadingly marketing the drug as a superior alternative to warfarin, a blood thinner that has been in use for decades. Among other things, the lawsuits point out that bleeding associated with warfarin can be stopped via the administration of vitamin K. However, there currently exists no approved reversal agent for Xarelto-induced bleeding events.

All federally-filed Xarelto lawsuits are currently centralized in a multidistrict litigation underway in the U.S. District Court, Eastern District of Louisiana, where more than 19,000 claims are pending. Three trials have already been convened in that proceeding, all of which concluded with defense verdicts.

Xarelto patients who allegedly experienced bleeding-related complications may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's “Plaintiffs' Hot List,” recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com

View original content with multimedia:

SOURCE Bernstein Liebhard LLP

Related Links

Powered by WPeMatico